A patient with coronary artery disease is to start low-dose aspirin therapy. What is the primary reason for this medication?

Choice A rationale Aspirin is a non-steroidal anti-inflammatory drug (NSAID) with analgesic properties, but it is not the primary reason for low-dose therapy in coronary artery disease. Aspirin's analgesic effect is achieved at higher doses. The primary goal of low-dose aspirin in this context is its antiplatelet effect, not pain relief, as it does not effectively address the chest pain associated with myocardial ischemia, which is typically managed with vasodilators like nitroglycerin. Choice B rationale Aspirin does not have a direct blood pressure-lowering effect. While it can reduce inflammation and vascular resistance in some cases, it is not prescribed as an antihypertensive medication. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and beta-blockers are the primary classes of medications used to manage high blood pressure in patients with coronary artery disease. Choice C rationale Low-dose aspirin inhibits the production of thromboxane A2 by irreversibly acetylating cyclooxygenase (COX-1) in platelets. Thromboxane A2 is a potent vasoconstrictor and platelet aggregator. By inhibiting its production, aspirin prevents platelets from clumping together, which reduces the risk of clot formation in the coronary arteries and helps prevent myocardial infarction and other cardiovascular events. Choice D rationale Aspirin does not significantly reduce cholesterol levels. Statin medications, such as atorvastatin or rosuvastatin, are the class of drugs primarily used to lower cholesterol. They work by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver. Aspirin's role is specifically to prevent thrombotic events, not to address the underlying lipid-related pathology.